Maxim Group reaffirmed their hold rating on shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in a report published on Wednesday.

“Shares of TEVA are under pressure in the wake of the FDA’s approval of Mylan’s ANDA for generic copaxone 3x/week & 20 mg/ml QD injection. Teva has a press release estimating the impact of the two launches to its 4Q earnings of at least $0.25. Our estimates are under review but our Hold remaining remains in-effect. We had anticipated generic copaxone (3x) but not until 2018.”,” Maxim Group’s analyst wrote.

Several other research analysts also recently commented on the stock. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries Limited from a strong sell rating to a hold rating in a research report on Wednesday. Oppenheimer Holdings, Inc. restated a hold rating on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday. Mizuho restated a hold rating and set a $16.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday. Barclays PLC set a $21.00 price objective on shares of Teva Pharmaceutical Industries Limited and gave the company an equal weight rating in a research report on Wednesday. Finally, BTIG Research reiterated a buy rating and set a $24.00 price target on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday. Five research analysts have rated the stock with a sell rating, eighteen have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Teva Pharmaceutical Industries Limited presently has a consensus rating of Hold and an average target price of $27.63.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 15.94 on Wednesday. The company’s 50-day moving average price is $16.91 and its 200-day moving average price is $26.76. The company’s market capitalization is $16.20 billion. Teva Pharmaceutical Industries Limited has a 52-week low of $15.22 and a 52-week high of $45.85.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the consensus estimate of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The firm had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. During the same quarter in the prior year, the firm earned $1.25 earnings per share. The firm’s revenue for the quarter was up 12.9% on a year-over-year basis. Equities research analysts forecast that Teva Pharmaceutical Industries Limited will post $4.28 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/10/08/teva-pharmaceutical-industries-limited-teva-stock-rating-reaffirmed-by-maxim-group.html.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 14th. Stockholders of record on Tuesday, August 29th were issued a dividend of $0.085 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $0.34 annualized dividend and a dividend yield of 2.13%. Teva Pharmaceutical Industries Limited’s dividend payout ratio is currently -15.36%.

Several hedge funds and other institutional investors have recently made changes to their positions in TEVA. Capital Research Global Investors raised its holdings in shares of Teva Pharmaceutical Industries Limited by 13.8% during the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after purchasing an additional 9,260,426 shares during the period. Franklin Resources Inc. raised its holdings in shares of Teva Pharmaceutical Industries Limited by 11.1% during the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after purchasing an additional 6,685,844 shares during the period. FMR LLC raised its holdings in shares of Teva Pharmaceutical Industries Limited by 16.7% during the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after purchasing an additional 6,115,853 shares during the period. Capital World Investors raised its holdings in shares of Teva Pharmaceutical Industries Limited by 41.9% during the second quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock valued at $367,686,000 after purchasing an additional 3,268,200 shares during the period. Finally, Alliancebernstein L.P. raised its holdings in shares of Teva Pharmaceutical Industries Limited by 32.3% during the second quarter. Alliancebernstein L.P. now owns 11,399,400 shares of the company’s stock valued at $378,688,000 after purchasing an additional 2,782,257 shares during the period. Hedge funds and other institutional investors own 56.77% of the company’s stock.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.